These reagents will give researchers doing experiments with knock-out and transgenic mice more options and allow for more complicated analytical studies to be done
Haematologic Technologies, a manufacturer of blood coagulation proteins and reagents, announces the introduction of a new line of reagents from murine source plasma.
These reagents will give researchers doing experiments with knock-out and transgenic mice more options and allow for more complicated analytical studies to be done.
Currently, Haematologic Technologies offers mouse prothrombin, thrombin, factor X, factor Xa, plasminogen and ATIII along with numerous polyclonal antibodies that are either directly against or that cross-react with these proteins.
Model systems are frequently used to study human bleeding disorders.
In the majority of model systems that have been developed, the murine phenotype compares well with the corresponding human deficiency thus making them ideal models for the study of human bleeding disorders.
In the simplest form, those models with complete factor deficiencies provide insight as to the lethalness (or survivability) of particular factor deficiencies.
For those factor deficiencies that allow survival for periods extending from birth to adulthood, the number of analytical tools that are available limits evaluation of the survivors.
Beyond pathological evaluation, coagulation assays are limited to simple bleeding time, PT and APTT assays, for which there is no standardisation. When model systems become more complicated as with partial deficiencies, concomitant factor deficiencies, mutated molecules, etc, the shortage of analytical tools becomes even more evident. Another perhaps even more expansive use of murine coagulation models is for new drug development.
During the course of developing new pro-coagulant, anti-coagulant and clot dissolving drugs, basic R and D studies as well as safety, efficacy, and pharmacokinetic studies are required.
Because both normal and genetically altered mice are available, the murine models are ideal for this application.
Haematologic Technologies says it plans on continuing its R and D efforts on its murine line, and is currently working on mouse factor IX, protein C, fibrinogen and plasmin.
